CR7660A - DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE - Google Patents

DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE

Info

Publication number
CR7660A
CR7660A CR7660A CR7660A CR7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A
Authority
CR
Costa Rica
Prior art keywords
composition
hours
average
pramipexole
absorption
Prior art date
Application number
CR7660A
Other languages
Spanish (es)
Inventor
J Lee Ernest
M Bredael Gerard
R Baldwin John
r cox Steven
J Heintz Mark
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CR7660A publication Critical patent/CR7660A/en

Links

Abstract

Se refiere a una composicion farmaceutica administrable oralmente que comprende una cantidad terapeuticamente eficaz de pramipexol o una de sus sales farmaceuticamente aceptable y al menos un excipiente farmaceuticamente aceptable, presentando dicha composicion al menos (a) un perfil de liberacion in vitro en el que en promedio no mas de 20% aproximadamente de pramipexol se disuelve en 2 horas despues de la colocacion de la composicion de ensayo de disolucion convencional, y (b) un perfil de absorcion de pramipexol in vivo despues de la administracion oral de una dosis a humanos adultos sanos, donde el tiempo para alcanzar una media de 20% de absorcion es mayor que 2 horas aproximadamente y/o el tiempo para alcanzar una media de 40% de absorcion es mayor que 4 horas aproximadamente. La composicion es util para administrarse oralmente no mas de una vez al dia a un sujeto que tenga una condicion o desorden para el cual sea indicado un agonista receptor de dopamina.It refers to an orally administrable pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition having at least (a) an in vitro release profile in which on average no more than about 20% of pramipexole dissolves in 2 hours after the placement of the conventional dissolution test composition, and (b) an absorption profile of pramipexole in vivo after oral administration of a dose to healthy adult humans , where the time to reach an average of 20% absorption is greater than about 2 hours and / or the time to reach an average of 40% absorption is greater than about 4 hours. The composition is useful for oral administration no more than once a day to a subject who has a condition or disorder for which a dopamine receptor agonist is indicated.

CR7660A 2002-07-25 2005-01-24 DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE CR7660A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25

Publications (1)

Publication Number Publication Date
CR7660A true CR7660A (en) 2005-06-08

Family

ID=38181237

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7660A CR7660A (en) 2002-07-25 2005-01-24 DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE

Country Status (2)

Country Link
CR (1) CR7660A (en)
TN (2) TNSN05019A1 (en)

Also Published As

Publication number Publication date
TNSN05020A1 (en) 2007-05-14
TNSN05019A1 (en) 2007-05-14

Similar Documents

Publication Publication Date Title
AR040682A1 (en) DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
JP6659072B2 (en) Melatonin agonist treatment
ES2577930T3 (en) Triazine derivatives to delay the onset of type 1 diabetes
AR040681A1 (en) COMPOSITION OF PRAMIPEXOL SUSTAINED RELEASE TABLETS
AR045972A1 (en) FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS
ES2579857T3 (en) Platelet rich plasma compositions
AR062320A1 (en) FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM
UY27627A1 (en) AZA - ARILPIPERAZINAS
SE0203065D0 (en) Gastric acid secretion inhibiting composition
AR045289A1 (en) ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT
NO20073403L (en) Use of atazanavir to improve the pharmacokinetics of drugs metabolized by UGT1A1
AR040709A1 (en) FORMULATION OF LAMOTRIGIN FOR LONG-TERM RELEASE AND USE OF THE SAME FOR PREPARATION
ATE505203T1 (en) PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN
AR062659A1 (en) COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE
CR7660A (en) DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION
AR046454A1 (en) USE OF A BENZAZEPIN-N-ACETIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION, AND PROCEDURE FOR THE PRODUCTION OF THE PHARMACEUTICAL COMPOSITION
CO5680422A2 (en) DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE
Fava The combination of buspirone and bupropion in the treatment of depression
Sayar et al. Girls Like to Chat with me If There is a Piece of Bupropion Under My Tongue
WACHTER Selegiline Safe, Effective as Adjunct for Parkinson’s
TH87764B (en) The dosage form of Pramipec Sol is once a day.
JP2009084253A (en) Prophylactic and/or therapeutic drug for headache
ECSP055749A (en) FORMULATION OF SUSTAINED RELEASE TRAILER WITH EFFECTIVENESS OF 24 HOURS

Legal Events

Date Code Title Description
FC90 Suspension of granting procedure